CYTOKINETICS INC (CYTK)
Health Care · NASDAQ
A biopharmaceutical company pioneering small-molecule cardiac myosin inhibitors and muscle-directed therapies to improve heart and neuromuscular function in patients with debilitating diseases.
What CYTOKINETICS INC does
Cytokinetics is a specialty biopharmaceutical company focused on discovering, developing, and commercializing small-molecule medicines that modulate muscle function and contractility. The company's first commercial product, MYQORZO (aficamten), is a cardiac myosin inhibitor approved by the FDA, EMA, and China NMPA for treating obstructive hypertrophic cardiomyopathy (oHCM). Beyond aficamten, the company has a pipeline of muscle-directed investigational therapies including omecamtiv mecarbil for heart failure, ulacamten for HFpEF, and CK-089 for muscular dystrophy, leveraging its proprietary expertise in muscle biology and cytoskeletal mechanics.
Themes: ["cardiac myosin inhibitors / hypertrophic cardiomyopathy"]
Fundamentals
- Price$86.07 as of 2026-07-09 close
- Market cap$10.5B as of 2026-07-10
- 1-year return+135.0% as of 2026-07-09 close
- Net margin-784.0% as of 2026-07-10
- ROE-131.2% as of 2026-07-10
- Debt / equity6.01 as of 2026-07-10
- Revenue growth (YoY)+450.6% as of 2026-07-10
- Revenue CAGR (3y)-2.4% SEC XBRL
- Beta0.32 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.